LBC
GILD icon

Leigh Baldwin & Co’s Gilead Sciences GILD Stock Holding History

Leigh Baldwin & Co’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$664K Buy
4,768
+2
+0% +$280 0.43% 54
2025
Q4 		$585K Buy
4,766
+2
+0% +$243 0.38% 63
2025
Q3 		$529K Buy
4,764
+101
+2% +$11.5K 0.3% 81
2025
Q2 		$517K Buy
+4,663
New +$496K 0.34% 79
2025
Q1 		– Sell
-4,660
Closed -$430K – 174
2024
Q4 		$430K Buy
+4,660
New +$420K 0.36% 80

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Leigh Baldwin & Co's GILD Position: Q1 2026 in Review

Leigh Baldwin & Co increased its Gilead Sciences (GILD) stake by 0.04% in Q1 2026, buying an estimated $280 and bringing the position to 4,768 shares worth $664K. The position accounts for 0.43% of the portfolio, ranked #54.

Leigh Baldwin & Co first reported a position in GILD in Q4 2024 and has held it in 5 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Leigh Baldwin & Co held 4,768 shares of Gilead Sciences worth $664K as of Q1 2026.
  • Leigh Baldwin & Co bought 2 Gilead Sciences shares in Q1 2026, an estimated $280.
  • Gilead Sciences made up 0.43% of Leigh Baldwin & Co's portfolio in Q1 2026, its #54 holding.
  • Leigh Baldwin & Co first reported a position in Gilead Sciences in Q4 2024 and has held it in 5 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Leigh Baldwin & Co's 13F filing for Q1 2026, filed 20 May 2026.